Immunotherapy with allergen peptides.

Area of Science:

• Immunology
• Allergy Research
• Peptide Therapeutics

Background:

• Specific allergen immunotherapy (SIT) is an effective disease-modifying treatment for allergies.
• Whole allergen preparations often cause adverse allergic events during SIT.
• Novel immunotherapy strategies aim to reduce allergenicity while preserving immunogenicity.

Purpose of the Study:

• To explore the use of short synthetic peptides representing dominant T cell epitopes for allergen immunotherapy.
• To assess the potential of peptide-based immunotherapy to reduce allergic adverse events.
• To maintain the immunogenicity of immunotherapy preparations.

Main Methods:

• Utilizing short synthetic peptides derived from dominant T cell allergen epitopes.
• Leveraging the reduced capacity of short peptides to cross-link IgE and activate immune cells.
• Conducting murine pre-clinical studies to establish feasibility.

Main Results:

• Short synthetic peptides demonstrate reduced allergenicity due to their lack of tertiary structure.
• Pre-clinical murine studies confirmed the feasibility of this peptide-based approach.
• Clinical studies are currently in progress for allergic and autoimmune diseases.

Conclusions:

• Short synthetic peptides represent a promising strategy for developing safer and effective allergen immunotherapy.
• This approach mitigates adverse events associated with traditional whole allergen immunotherapy.
• Further clinical evaluation is ongoing to validate efficacy in human subjects.